Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients

Florian Rosar; Kalle Ribbat; Martin Ries; Johannes Linxweiler; Mark Bartholomä; Stephan Maus; Mathias Schreckenberger; Samer Ezziddin; Fadi Khreish

doi:10.1186/s13550-020-00640-2

Neuron-specific enolase has potential value as a biomarker for [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients

EJNMMI Res. 2020 May 24;10(1):52. doi: 10.1186/s13550-020-00640-2.

Authors

Florian Rosar¹, Kalle Ribbat², Martin Ries², Johannes Linxweiler³, Mark Bartholomä², Stephan Maus², Mathias Schreckenberger⁴, Samer Ezziddin², Fadi Khreish²

Affiliations

¹ Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany. florian.rosar@uks.eu.
² Department of Nuclear Medicine, Saarland University-Medical Center, Kirrberger Str. 100, Geb. 50, 66421, Homburg, Germany.
³ Department of Urology, Saarland University-Medical Center, Homburg, Germany.
⁴ Department of Nuclear Medicine, University of Mainz, Mainz, Germany.

Abstract

Background: PSMA-targeted radioligand therapy (PSMA-RLT) yielded impressive results in the metastasized castration-resistant prostate carcinoma (mCRPC) setting. High expression of PSMA is essential for successful PSMA-RLT. However, some patients develop [¹⁸F]FDG-avid lesions with low or no PSMA expression ([¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch findings on PET/CT) in the course of treatment. Those lesions are not affected by PSMA-RLT and a change in therapy management is needed. To enable early mismatch detection, possible blood parameters as indicators for the occurrence of [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch findings on PET/CT were evaluated.

Methods: Retrospective study of N = 66 advanced mCRPC patients with dual [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FDG PET/CT imaging within 4 weeks, who were referred for or received [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy. Prostate-specific antigen (PSA), neuron-specific enolase (NSE), gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP) were tested as indicators for the occurrence of [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch findings. Additional to absolute values, relative changes (ΔPSA, ΔNSE, ΔGGT, ΔALP) over a period of 4 ± 1 weeks prior to [¹⁸F]FDG PET/CT were analyzed.

Results: In total, 41/66 (62%) patients revealed at least one [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch finding on PET/CT. These mismatch findings were detected in 13/41 (32%) patients by screening for and in 28/41 (68%) patients during PSMA-RLT. NSE serum level (55.4 ± 44.6 μg/l vs. 18.5 ± 8 μg/l, p < 0.001) and ΔNSE (93.8 ± 124.5% vs. 2.9 ± 39.5%, p < 0.001) were significantly higher in the mismatch group than in the non-mismatch group. No significant differences were found for serum PSA (p = 0.424), ΔPSA (p = 0.417), serum ALP (p = 0.937), ΔALP (p = 0.611), serum GGT (p = 0.773), and ΔGGT (p = 0.971). For NSE and ΔNSE, the maximum value of the Youden index in ROC analysis was at a cut-off level of 26.8 μg/l (sensitivity 78%, specificity 96%) and at + 13.9% (sensitivity 84%, specificity 75%), respectively. An introduced scoring system of both parameters achieved a sensitivity of 90% and a specificity of 88% for the occurrence of [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch.

Conclusion: We observed a significantly higher absolute serum concentration and a higher relative increase of NSE in advanced mCRPC patients with [¹⁸F]FDG-avid and insufficient PSMA expressing metastases ([¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch findings on PET/CT) in our cohort. NSE might be used as a potential laboratory indicator for [¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA-11 mismatch findings, if this observation is confirmed in future, ideally prospective, studies in larger patient cohorts.

Keywords: FDG PET/CT; Mismatch; PSMA PET/CT; Prostate cancer; mCRPC.